Makoto Ueno
Expertise in
13
conditions

Makoto Ueno

Yokohama, JP 
Expertise in
13
conditions
Yokohama, JP 

Overview

Makoto Ueno practices practicing medicine in Yokohama, Japan.

Mr. Ueno is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Pancreatectomy.

He is actively involved in clinical research, co-authoring 277 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Yokohama, 2418515, Japan
Other Locations
Tokyo, Japan
Shinjuku, 1608582, Japan
Kanagawa, Japan
Kanazawa, Japan
Tanabe, Japan
Shizuoka, 4118777, Japan
Katsura, 6158510, Japan
Osaka, 5900482, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Drug
Study Drug: M7824
Study Phase: Phase 2
View 1 Less Clinical Trial

277 Total Publications

Early steroid initiation may improve outcomes in immune checkpoint inhibitor-related cholangitis: a multicenter cohort study.
Early steroid initiation may improve outcomes in immune checkpoint inhibitor-related cholangitis: a multicenter cohort study.
Journal: Immunological medicine
Published: July 06, 2026

Frequently Asked Questions about Makoto Ueno

Is Makoto Ueno a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Makoto Ueno is classified as an Elite expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Makoto Ueno participate in research or clinical trials?

Yes. Makoto Ueno has published 277 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Makoto Ueno's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ueno's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 54 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile